Home › Kanser sa Baga › Georgia › Atlanta
Pag-aaral pangklinika para sa Kanser sa Baga sa Atlanta, GA
29 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Atlanta (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Northside Hospital, Atlanta
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Nagre-recruitPhase 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Atlanta VA Medical Center, Decatur · 6 mi ang layo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- at 1 pa
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Nagre-recruitPhase 3
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Nagre-recruitPhase 3
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Nagre-recruitPhase 2/3
- Piedmont Healthcare, Atlanta
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Nagre-recruit
- Emory Clinic at Old Fourth Ward, Atlanta
- Emory Clinic at Midtown, Atlanta
- Emory at Peachtree Hills - Primary Care, Atlanta
- at 19 pa
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Piedmont Cancer Institute, PC, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Nagre-recruitPhase 1
- Emory University, Atlanta
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Nagre-recruitPhase 1/2
- Avenzo Therapeutics Recruiting Site, Atlanta
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Nagre-recruitPhase 3
- Northside Hospital Atlanta, Atlanta
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nagre-recruitPhase 1
- Emory University - Winship Cancer Institute, Atlanta
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Grady Health System, Atlanta
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
- at 3 pa
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Xencor Investigative Site, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- Winship Cancer Institute - Emory University, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Northside Hospital, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Nagre-recruitPhase 1/2
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- at 3 pa
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Nagre-recruitPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 1
- Emory University Hospital/Winship Cancer Institute, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Nagre-recruitMaagang Phase 1
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Nagre-recruitPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Nagre-recruitObservasyonal na pag-aaral
- Northside Hospital, Atlanta
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Nagre-recruitPhase 1
- Emory University Hospital Midtown, Atlanta
- Emory University, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Atlanta
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Chicago, IL41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
Iba pang pag-aaral sa Atlanta
- Kanser (lahat ng uri)49 pag-aaral
- Non-Small Cell Lung Cancer47 pag-aaral
- Multiple Myeloma42 pag-aaral
- Kanser sa Suso41 pag-aaral
- Kanser sa Prostate33 pag-aaral
- Acute Myeloid Leukemia31 pag-aaral
- Kanser sa Ovary29 pag-aaral
- Colorectal Cancer29 pag-aaral
- Metastatic Cancer28 pag-aaral
- Major Depressive Disorder25 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg24 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.